Development of potent monoclonal antibody auristatin conjugates for cancer therapySvetlana O. Doronina, Peter D. Senter, Tim D. Bovee et al.|Nature Biotechnology|2003Cited by 1.2k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityJoseph A. Francisco, Alan F. Wahl, Charles G. Cerveny et al.|Blood|2003Cited by 918
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicitySvetlana O. Doronina, Peter D. Senter, Brian A. Mendelsohn et al.|Bioconjugate Chemistry|2005Cited by 511
<i>In vivo</i>Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin ImmunoconjugateRussell J. Sanderson, Alan F. Wahl, Stephanie James et al.|Clinical Cancer Research|2005Cited by 280